Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +84.09% and +18.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Castle Biosciences Reports Second Quarter 2026 Results
Castle Biosciences Reports Second Quarter 2026 Results Castle Biosciences Reports Second Quarter 2026 Results PR Newswire FRIENDSWOOD, Texas, July 30, 2026 Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx-Melanoma, TissueCypher...
PR Newswire
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference PR Newswire FRIENDSWOOD, Texas, July 22, 2026 FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc.(Nasdaq...
PR Newswire
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test PR Newswire FRIENDSWOOD, Texas, July 14, 2026 Approval expands access to Castle's precision medicine...
PR Newswire
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire FRIENDSWOOD, Texas, July 9, 2026 FRIENDSWOOD, Texas, July 9...
PR Newswire
DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire FRIENDSWOOD, Texas, June 25...
PR Newswire
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire FRIENDSWOOD, Texas, June 23, 2026 Stokes was...
PR Newswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire FRIENDSWOOD, Texas, June 19, 2026 FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq...
PR Newswire
Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire...
PR Newswire
Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics...
PR Newswire